Search
How to apply for an EHA Research Grant
On this page, we explain all of the actions you'll need to take when submitting a grant application. You can also get a basic overview of the process in our EHA Research Grants diagram.
Read moreEU pilot on drug repurposing
Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.
Read moreSWG Educational Activities
MeetingsSWG meetingsThe SWG on Transfusions holds monthly meetings. EHA CongressOne focus is support for all activities of the EHA Congress. At the EHA 2023 Congress, which was held in Frankfurt, some sessions on transfusion were supported virtually.
Read moreSponsor and Fundraising Committee
Current committee members
Martin Dreyling, Germany (Chair)
Claire Harrison, United Kingdom (Vice-Chair)
Igor Aurer, Croatia (SWG Committee representative)
Arndt Borkhardt, Germany (Research Committee representative)
Konstanze Döhner, Germany (Education Committee representative)
Kirsten Grønbæk, Denmark (Councilor)
Frank Leebeek, The Netherlands (Councilor)
Mariane de Montalembert, France (Councilor)
David Rees, United Kingdom (Education…
Highlights from the SWG
The SWG:
Was involved with the European Medicines Agency (EMA) on shortages—as part of our policy and regulatory work
Participated in the EMA Healthcare Professionals Policy Officers' Group (HCP POG) review of the ‘Frailty and Older People: Considerations in Medicine Development and…
Last chance: special EAPM2017 registration offer for EHA members
EAMP2017 will take place in Belfast, Ireland, from 27-29 November 2017. The European Alliance for Personalised Medicine (EAPM), launched in March 2012, brings together European healthcare experts and patient advocates involved with major chronic diseases.
Read moreSWG Educational Activities
In 2021, the SWG on Multiple Myeloma contributed a major part of the ESMO-EHA guidelines for multiple myeloma. The rapid changes of the treatment landscape for this disease require an adaptation of the guidelines.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- »